治疗救济公司在SSIEM 2024上介绍了PKU GOLIKE®试验的临时发现,显示了降低PKU儿童的Phe水平的潜力. Relief Therapeutics presents interim findings of PKU GOLIKE® trial at SSIEM 2024, showing potential for lowering Phe levels in children with PKU.

瑞士生物制药公司Relife Therapeutics将在SSIEM 2024年度研讨会上展示其PKU GOLIKE®临床试验的临时发现. Relief Therapeutics, a Swiss biopharmaceutical firm, will present interim findings from its clinical trial of PKU GOLIKE® at the SSIEM 2024 Annual Symposium. 这项在伯明翰儿童医院进行的研究评估了PKU GOLIKE与标准氨基酸替代品相比在治疗患有基尿症 (PKU) 的儿童的夜间氨 (Phe) 水平方面的有效性. The study, conducted at Birmingham Children's Hospital, assessed PKU GOLIKE's effectiveness compared to standard amino acid substitutes in managing overnight phenylalanine (Phe) levels in children with phenylketonuria (PKU). 预先的结果显示PKU GOLIKE可能降低Phe并提高提洛辛水平. Preliminary results show PKU GOLIKE may lower Phe and raise tyrosine levels. 在进一步进行数据分析之后,将得出最后结果。 Final results will follow further data analysis.